The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.
With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...
If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...
Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – ...
EST Cathie Wood’s ARK Investment bought 147K shares of Crispr Therapeutics (CRSP) todayStay Ahead of the Market:Discover outperforming ...
We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...
"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...
Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback